Objective <p>Immunotherapy with dinutuximab beta (DB) improves the prognosis of patients with high-risk neuroblastoma (HR-NB) but can be associated with severe immune-mediated side effects. A comprehensive side effect management is necessary to improve tolerability and avoid treatment discontinuation. To date, standardized guidelines on co-medication and on the management of acute and chronic side effects are not available in Germany. In a&#xa0;survey, German pediatric oncology departments were therefore asked about their experiences and procedures from which the recommendations described here were developed.</p> Method <p>A&#xa0;survey was conducted among German pediatric oncology centers to assess their approaches to managing DB-related adverse effects. Centers were asked about their experiences and procedures, and consensus recommendations were subsequently developed by an expert panel based on these findings.</p> Results <p>Existing international recommendations were expanded by incorporating current clinical practices from German centers, resulting in comprehensive guidelines for adverse event management during DB immunotherapy.</p> Conclusion <p>These recommendations can contribute to improving tolerability and thereby help prevent treatment discontinuation.</p>